MoonLake Immunotherapeutics achieves landmark milestone with positive Phase 2 results for Nanobody® sonelokimab in hidradenitis suppurativa

-First placebo-controlled randomized trial in HS to report positive topline results using HiSCR75 as the primary endpoint
-Primary endpoint HiSCR75 met with 29 percentage points (ppt) delta vs placebo (p=0.0002) at week 12, setting a new bar in HS
-HiSCR50 met with 38 ppt delta vs placebo (p